ArticleCancer biomarkers : section A of Disease markers2018
Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia.
Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic and Prognostic Role of miR-192 in Different Cancers: A Systematic Review and Meta-Analysis.BioMed research international · 2021Pooled it
- The Potential Diagnostic Accuracy of Circulating MicroRNAs for Leukemia: A Meta-Analysis.Technology in cancer research & treatmentPooled it
- Advancing Leukemia Management Through Liquid Biopsy: Insights into Biomarkers and Clinical Utility.Cancers · 2025Review
- Role of MicroRNAs in Acute Myeloid Leukemia.Genes · 2025Review
- Molecular mechanisms of miR-192 in cancer: a biomarker and therapeutic target.Cancer cell international · 2025Review
- MiRNA expression as outcome predictor in pediatric AML: systematic evaluation of a new model.NPJ genomic medicine · 2024Article
- A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.Clinical epigenetics · 2023Article
- Circular RNAs: pivotal role in the leukemogenesis and novel indicators for the diagnosis and prognosis of acute myeloid leukemia.Frontiers in oncology · 2023Review
- Identification of immunity-related lncRNAs and construction of a ceRNA network of potential prognostic biomarkers in acute myeloid leukemia.Frontiers in genetics · 2023Article
- One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.Epigenomes · 2021Review
- A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma.Cell death & disease · 2021Article
- Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs.International journal of molecular sciences · 2020Article
- Overview of current microRNA biomarker signatures as potential diagnostic tools for leukaemic conditions.Non-coding RNA research · 2020Review
- MicroRNA-192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K/AKT pathway.World journal of surgical oncology · 2020Article
- High serum extracellular vesicle miR-10b expression predicts poor prognosis in patients with acute myeloid leukemia.Cancer biomarkers : section A of Disease markers · 2020Article
- Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia.Journal of hematology & oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbnormal expression of miR-192 has been observed in a variety of human cancers, but the expression pattern of miR-192 and its prognostic value in pediatric acute myeloid leukemia (AML) is poorly known.
objectiveThis study was to explore the expression status of miR-192 and its clinical significance in pediatric patients with AML.
methodsQuantitative RT-PCR was carried out to detect miR-192 expression level in the serum from 97 AML cases and 50 healthy controls.
resultsThe results showed that downregulation of serum miR-192 was observed in pediatric AML patients and strongly correlated with aggressive clinical features. Increased serum miR-192 expression occurred more frequently in the AML subjects with favorable risk cytogenetics. Moreover, serum miR-192 expression showed good performance to screen pediatric AML subjects from normal controls. Furthermore, serum miR-192 was identified as a independent prognostic indicator for both overall survival and event free survival. In addition, low serum miR-192 expression significantly contributed to poor prognosis in the whole cohort of AML patients or the AML patients with intermediate-risk cytogenetics.
conclusionsCollectively, serum miR-192 potentially can be a reliable biomarker for the diagnosis and prognosis in pediatric AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.